Thirty-two outbreaks of hepatitis A associated with drinking water were identified during 1971 to 2017, and all occurred before 2010.
For adults with noninfectious uveitis, mycophenolate mofetil is not associated with superior control of inflammation compared with methotrexate.
The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.
Patients with porphyria cutanea tarda have increased all-cause mortality and risk for death because of gastrointestinal diseases and cancer of the gut, liver, gallbladder, and lungs.
FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.
Synthetic Biotic medicines utilize synthetic biology to reprogram probiotic bacteria to perform critical functions that compensate for those missing or damaged due to a particular disease.
Researchers identified a strong relationship between significant comorbidity burden and outcomes of patients with suspected drug-induced liver injury, and developed and validated a model to calculate risk of death within 6 months.
Two risk stratification models, GLOBE and UK-PBC, performed well in predicting future complications related to cirrhosis in patients with primary biliary cholangitis.
A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.
Type 2 diabetes mellitus (T2DM) is a risk factor for progression of liver fibrosis in patients with nonalcoholic fatty liver disease.